http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Empirical study on the impact of PM<sub>10</sub> on mortality rate in China
( Ding Lin ),( Akira Hibiki ) 한국환경경제학회·한국자원경제학회(구 한국환경경제학회) 2018 한국환경경제학회 학술발표논문집 Vol.2018 No.하계
This paper investigates the impact of PM<sub>10</sub> on mortality throughout 31 provinces in China by using dynamic panel data model. The results show PM<sub>10</sub> has significant negative impact on mortality rate in the long term. Higher income reduces the mortality rate, as well as reduces the impact of PM<sub>10</sub> on mortality rate. Provinces with higher increasing rate in PM<sub>10</sub> bring out more increasing in mortality rate. With increasing in PM<sub>10</sub> by 0.01 mg/m<sup>3</sup> (6.9%, 24.61%), death toll will be increased by at most 0.2188 per thousand people. If the government adopt measures to reduce PM<sub>10</sub> concentration, the death toll is reduced by (285679.09, 370132.46) for reaching Chinese national standard and (1218762.97, 1549211.57) for WHO’s standard.
Zeng, Yin-Duo,Zhang, Li,Liao, Hai,Liang, Ying,Xu, Fei,Liu, Jun-Ling,Dinglin, Xiao-Xiao,Chen, Li-Kun Asian Pacific Journal of Cancer Prevention 2012 Asian Pacific journal of cancer prevention Vol.13 No.3
Background: Gefitinib, a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), is used both as a single drug and concurrently with whole brain radiotherapy (WBRT) the standard treatment for brain metastases (BM), and is reported to be effective in a few small studies of patients with BM from non-small-cell lung cancer (NSCLC). However, no study has compared the two treatment modalities. This retrospective analysis was conducted to compare the efficacy of gefitinib alone with gefitinib plus concomitant WBRT in treatment of BM from NSCLC. Methods: We retrospectively reviewed 90 patients with BM from NSCLC who received gefitinib alone (250mg/day, gefitinib group) or with concomitant WBRT (40Gy/20f/4w, gefitinib-WBRT group) between September 2005 and September 2009 at Sun Yat-Sen University Cancer Center. Forty-five patients were in each group. Results: The objective response rate of BM was significantly higher in gefitinib-WBRT group (64.4%) compared with gefitinib group (26.7%, P<0.001). The disease control rate of BM was 71.1% in gefitinib-WBRT group and 42.2% in gefitinib group (P=0.006). The median time to progression of BM was 10.6 months in gefitinib-WBRT group and 6.57 months in gefitinib group (P<0.001). The median overall survival(OS) of gefitinib-WBRT and gefitinib alone group was 23.40 months and 14.83 months, respectively (HR, 0.432, P=0.002). Conclusion: Gefitinib plus concomitant WBRT had higher response rate of BM and significant improvement in OS compared with gefitinib alone in treatment of BM from NSCLC.